Thursday, June 11, 2026
🇺🇸 FDA

pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp clinical programs — 82 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

MSD Merck Sharp projects

82 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.

MSD Merck Sharp has 82 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

82 programs

Clinical programs

Page 2 of 2

  1. MK-3475-B98

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  2. MK-3475-B99

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  3. MK-3475A

    Merck Sharp and Dohme

    Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

    phase 2 small molecule active

    1 trial

  4. MK-3475A-F11

    Merck Sharp and Dohme

    Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  5. MK-4830-002

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 small molecule active

    1 trial

  6. MK-5592-127

    Merck Sharp and Dohme

    Fungal infection

    phase 2 small molecule active

    1 trial

  7. MK-5684-01A

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  8. MK-6024-017

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  9. MK-6070-002

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  10. MK-7684A-005

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  11. MK-7902-009

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  12. MK-7902-013

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

  13. MK-7962-023

    Merck Sharp and Dohme

    Pulmonary Hypertension

    phase 2 small molecule active

    1 trial

  14. MK-7962-024

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  15. MK-7962-031

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  16. MK-8591-013

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  17. MK-9999-01C

    Merck Sharp and Dohme

    Hepatoblastoma, Rhabdomyosarcoma

    phase 2 small molecule active

    1 trial

  18. MK-9999-02A

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  19. MS200095-0031

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  20. MS200569_0003

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  21. MS201924_0002

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  22. MS201924_0022

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial

  24. Placebo to MK-6194, MK-6194

    Merck Sharp and Dohme

    Non segmental vitiligo

    phase 2 small molecule active

    1 trial

  25. SOTATERCEPT, sotatercept

    Merck Sharp and Dohme

    Pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  26. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  27. V940-004

    Merck Sharp and Dohme

    Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy.

    phase 2 small molecule active

    1 trial

  28. V940-005

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  29. V940-012

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  30. V940-013

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  31. Zilovertamab vedotin

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  32. mRNA-4157, BCG VACCINE

    Merck Sharp and Dohme

    Bladder cancer

    phase 2 small molecule active

    1 trial

  33. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial

  34. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does MSD Merck Sharp have?

82 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.